Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-11-11
|
cabiralizumab (FPA008) and nivolumab |
advanced solid tumors including pancreatic cancer |
1a-1b |
Five Prime Therapeutics (USA - CA) BMS (USA - NY) |
Cancer - Oncology |
2017-11-10
|
avapritinib (BLU-285) |
gastrointestinal stromal tumors (GIST) |
1 |
Blueprint Medicines (USA - MA) |
Cancer - Oncology - Rare diseases |
2017-11-10
|
RTH258 |
neovascular wet age-related macular degeneration (AMD) |
3 |
Alcon (USA -TX), a Novartis subsidiary (Switzerland) |
Ophtalmological diseases |
2017-11-09
|
MVA-BN® RSV vaccine |
respiratory syncytial virus infections |
2 |
Bavarian Nordic (Denmark) |
Infectious diseases |
2017-11-08
|
Leukotide |
acute myeloid leukemia and other hematological malignancies |
preclinical |
Medivir (Sweden) |
Cancer - Oncology |
2017-11-06
|
ADV7103 (tripotassium citrate monohydrate and potassium hydrogen carbonate) |
distal renal tubular acidosis (dRTA) |
3 |
advicenne |
Rare diseases |
2017-11-06
|
WVE-210201 |
Duchenne muscular dystrophy (DMD) |
1 |
Wave LIfe Sciences (USA - MA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2017-11-06
|
UCART123 |
acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) |
1 |
Cellectis (France) |
Cancer - Oncology |
2017-11-04
|
AS902330 (sprifermin) |
primary osteoarthritis of the knee |
2b |
Merck KGaA (Germany) |
Inflammatory diseases - Rheumatic diseases |
2017-11-03
|
sparsentan (RE-021) |
focal segmental glomerulosclerosis (FSGS) |
2 |
Retrophin (USA - CA) |
Rare diseases - Kidney diseases - Renal diseases |
2017-11-02
|
Ionis-TTRRx - inotersen |
TTR amyloid cardiomyopathy |
3 |
GSK (UK) Ionis Pharmaceuticals (USA - CA) |
Rare diseases - Genetic diseases |
2017-11-01
|
avapritinib (BLU-285) |
gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM) |
preclinical |
Blueprint Medicines (USA - MA) |
Cancer - Oncology - Rare diseases |
2017-11-01
|
elagolix |
endometriosis |
3 |
Abbvie (USA - IL) Neurocrine Biosciences (USA - CA) |
Women health |
2017-11-01
|
AVXS-101 |
spinal muscular atrophy (SMA) Type 1 |
1-2 |
Avexis (USA - TX), now a Novartis company (Switzerland) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2017-11-01
|
SYNT001 |
autoimmune diseases that are dependent upon IgG |
1a |
Syntimmune (USA - MA) |
Autoimmune diseases |
2017-11-01
|
SYNT001 |
Warm Autoimmune Hemolytic Anemia (WAIHA) |
1 |
Syntimmune (USA - MA) |
Autoimmune diseases - Rare diseases |
2017-11-01
|
REGN2810 (cemiplimab) and INO-5401 |
glioblastoma |
1b/2a |
Inovio Pharmaceuticals (USA - PA) |
Cancer - Oncology - Rare diseases |
2017-10-31
|
AR101 |
peanut-allergic children and adolescents 4-17 years of age |
2 |
Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) |
Allergic diseases |
2017-10-27
|
EB8018 |
Crohn's disease |
1 |
Enterome Bioscience (France) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2017-10-27
|
tazemetostat - EPZ-6438 (E7438) |
pediatric patients with relapsed or refractory INI1-negative molecularly defined solid tumors |
1 |
Epizyme (USA - MA) |
Cancer - Oncology |